Research programme: HCV replication inhibitors - Chugai
Alternative Names: CH 8755; NA 255; Orally available serine palmitoyltransferase inhibitors - ChugaiLatest Information Update: 04 Nov 2017
At a glance
- Originator Chugai Pharmaceutical
- Class Small molecules
- Mechanism of Action Hepatitis C virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-C in Japan (PO)
- 23 Aug 2012 Preclinical development is ongoing in Japan
- 03 Apr 2009 Preclinical development is ongoing in Japan